公开(公告)号：US20150158935A1

公开(公告)日：2015-06-11

申请号：US14413939

申请日：2013-07-09

申请人： Merck Sharp & Dohme Corp. ,  Merck Sharp & Dohme Corp.

发明人： Tessie B. McNeely ,  Leslie Cope ,  Gregory D. Pancari ,  Amita Joshi

IPC分类号： C07K16/12 ,  A61K39/085 ,  C07K14/31

CPC分类号： C07K16/1271 ,  A61K39/085 ,  A61K2039/55505 ,  C07K14/31 ,  C07K2317/24

摘要： The present invention relates to methods of inducing an immune response to Staphylococcus comprising administering a composition comprising an SA2493-related polypeptide from Staphylococcus aureus as well as derivatives or fragments there-of. The present invention also encompasses methods of treating and/or reducing the likelihood of a Staphylococcus infection by administering a composition comprising an SA2493-related polypeptide or an antibody that specifically binds to an SA2493 polypeptide, derivative or fragments thereof. Compositions administered in the methods of the invention can include one or more additional antigens including, but not limited to, IsdB. Compositions used to practice the methods of the invention are also encompassed.

摘要翻译： 本发明涉及诱导对葡萄球菌的免疫应答的方法，包括从金黄色葡萄球菌及其衍生物或片段施用包含SA2493相关多肽的组合物。 本发明还包括通过施用包含与SA2493多肽或其衍生物或片段特异性结合的SA2493相关多肽或抗体的组合物来治疗和/或降低葡萄球菌感染的可能性的方法。 在本发明的方法中施用的组合物可以包括一种或多种另外的抗原，包括但不限于IsdB。 也包括用于实施本发明方法的组合物。

公开(公告)号：US20230416266A1

公开(公告)日：2023-12-28

申请号：US18038367

申请日：2021-11-23

申请人： Merck Sharp & Dohme Corp.

发明人： Yongxin Han ,  Elisabeth Hennessy ,  Andrew J. Hoover ,  Jesus Moreno ,  Uma Swaminathan

IPC分类号： C07D491/052 ,  A61P35/00

CPC分类号： C07D491/052 ,  A61P35/00

摘要： The disclosure provides compounds of Formula (I)




or a pharmaceutically acceptable salt thereof, wherein W1, W2, Y, Z, CA, R1, R2a, and R2b are as described herein. The compounds or their pharmaceutically acceptable salts can inhibit the G12C mutant of Kirsten rat sarcoma (KRAS) protein and are expected to have utility as therapeutic agents, for example, for treating cancer. The disclosure also provides pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cancer and for preparing pharmaceuticals for this purpose.

公开(公告)号：US11854664B2

公开(公告)日：2023-12-26

申请号：US16973175

申请日：2019-06-11

申请人： Merck Sharp & Dohme Corp.

发明人： Arthur Fridman ,  Ansuman Bagchi ,  Xiang Yu ,  Mark Cancilla

IPC分类号： G16B15/00 ,  G06F16/2455 ,  G16C20/20 ,  G16C20/80 ,  G16C20/40 ,  G06F16/901 ,  G16C20/90

CPC分类号： G16B15/00 ,  G06F16/2455 ,  G06F16/9024 ,  G16C20/20 ,  G16C20/40 ,  G16C20/80 ,  G16C20/90

摘要： Embodiments of the present invention provide a computer-implemented system and method for generating and searching a database containing all of the potential substructures (e.g., metabolites) of a chosen complex molecule based on minimum cleavable units (MCUs) of the chosen complex molecule, wherein each record in the generated database suitably defines the molecular weight and physical arrangement of each substructure. Embodiments of the invention also provide a user interface and a search engine for searching the database based on a query molecular weight (or query molecular weight range) to identify all of the substructures having a total molecular weight matching the query molecular weight or range. Embodiments of the invention are also capable of transmitting to a display device operated by an end user a description and/or a graphical representation of every identified substructure of the chosen complex molecule.

公开(公告)号：US20230391758A1

公开(公告)日：2023-12-07

申请号：US18043413

申请日：2021-09-15

申请人： MERCK SHARP & DOHME CORP.

发明人： Michael J. Breslin ,  Mark E. Fraley ,  Melissa C. Ford ,  Kristen L.G. Jones, SR. ,  Anthony J. Roecker ,  Kathy M. Schirripa ,  Ling Tong

IPC分类号： C07D405/12 ,  C07D471/04 ,  C07D307/85 ,  C07D405/06 ,  C07D453/02 ,  C07D405/14 ,  C07D413/12

CPC分类号： C07D405/12 ,  C07D471/04 ,  C07D307/85 ,  C07D405/06 ,  C07D453/02 ,  C07D405/14 ,  C07D413/12

摘要： The present invention relates to Compounds of Formula I: and pharmaccutically acceptable salts or prodrug thereof. The present invention also relates to compositions comprising at least one compound of Formula I, and methods of using the compounds of Formula I for treatment or prophylaxis of lysosomal storage diseases, neurodegenerative disease, cystic disease, cancer, or a diseases or disorders associated with elevated levels of glucosylceramide (GlcCer), glucosylsphingosine (GlcSph) and/or other glucosylceramide-based glycosphingolipids (GSLs).

公开(公告)号：US11820805B2

公开(公告)日：2023-11-21

申请号：US16771818

申请日：2018-12-13

申请人： Merck Sharp & Dohme Corp. ,  Lin Yan ,  Pei Huo ,  Ahmet Kekec ,  Danqing D. Feng ,  Yuping Zhu ,  Dmitri Pissarnitski ,  Chris Moyes ,  Songnian Lin

发明人： Lin Yan ,  Pei Huo ,  Ahmet Kekec ,  Danqing D. Feng ,  Yuping Zhu ,  Dmitri Pissarnitski ,  Chris Moyes ,  Songnian Lin

IPC分类号： C07K14/62 ,  A61K47/61 ,  A61K47/54 ,  A61K38/00

CPC分类号： C07K14/62 ,  A61K47/549 ,  A61K47/61 ,  A61K38/00

摘要： The present disclosure provides conjugates that comprise an insulin molecule conjugated via a conjugate framework to two or more separate ligands that each include a saccharide, wherein the framework, ligand, saccharide and insulin molecule optionally comprise a fatty chain (e.g., a C8-30 fatty chain), wherein when said insulin molecule is conjugated both to a C8-30 fatty chain and one or more separate ligands that each include a saccharide, said C8-30 fatty chain is linked to insulin molecule only, and wherein when the framework or ligand comprises a fatty chain the insulin molecule is conjugated to two or more separate ligands. In certain embodiments, a conjugate is characterized in that, when the conjugate is administered to a mammal, at least one pharmacokinetic (PK) and/or pharmacodynamic (PD) property of the conjugate is sensitive to serum concentration of a second saccharide. In certain embodiments, a conjugate is also characterized by having a protracted PK profile. Exemplary conjugates and sustained release formulations are provided in addition to methods of use and preparation.

公开(公告)号：US11802122B2

公开(公告)日：2023-10-31

申请号：US17347639

申请日：2021-06-15

申请人： Merck Sharp & Dohme Corp.

发明人： Ashok Arasappan ,  Ian M. Bell ,  Christopher James Bungard ,  Christopher S. Burgey ,  Jason M. Cox ,  Michael J. Kelly, III ,  Mark E. Layton ,  Hong Liu ,  Jian Liu ,  James J. Perkins ,  Akshay A. Shah ,  Michael David VanHeyst ,  Zhe Wu

IPC分类号： C07D403/12 ,  C07D233/32 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12 ,  C07D413/12 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D471/08 ,  C07D513/04 ,  A61K31/4166 ,  A61P25/00 ,  A61P25/04 ,  A61P29/00

CPC分类号： C07D403/12 ,  C07D233/32 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12 ,  C07D413/12 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D471/08 ,  C07D513/04

摘要： Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Nav1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by Nav1.8 channel activity. The compounds of the present invention may be useful in the treatment, prevention or management of pain disorders, cough disorders, acute itch disorders, and chronic itch disorders.

公开(公告)号：US11739143B2

公开(公告)日：2023-08-29

申请号：US17122325

申请日：2020-12-15

申请人： TEIJIN PHARMA LIMITED ,  MERCK SHARP & DOHME CORP.

发明人： Hiroshi Eguchi ,  Takashi Murakami ,  Naoko Namiki ,  Akira Tanokura ,  Jeanne E. Baker ,  Sophie Parmentier Batteur ,  Angela Marie Jablonski ,  Daniel Stephen Malashock ,  Carl Mieczkowski ,  Gopalan (Raghu) Raghunathan

IPC分类号： C07K16/28 ,  C07K16/18 ,  A61P25/16 ,  A61P25/28 ,  C07K16/06 ,  C07K16/40 ,  C07K16/44

CPC分类号： C07K16/28 ,  A61P25/16 ,  A61P25/28 ,  C07K16/065 ,  C07K16/18 ,  C07K16/40 ,  C07K16/44 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/92 ,  C07K2317/94

摘要： The invention provides methods for using and compositions of humanized antibodies that bind tau protein that is phosphorylated at the serine at position 413.

公开(公告)号：US11738010B2

公开(公告)日：2023-08-29

申请号：US17385258

申请日：2021-07-26

申请人： MERCK SHARP & DOHME CORP.

发明人： John P. Caldwell ,  Reynalda De Jesus ,  Fa-Xiang Ding ,  Charles J. Gill ,  Ginny Dai Ho ,  Sookhee N. Ha ,  Sandra J. Koseoglu ,  Marc A. Labroli ,  Sang Ho Lee ,  Christina Madsen-Duggan ,  Mihir Mandal ,  Terry Roemer ,  Jing Su ,  Christopher Michael Tan ,  Zheng Tan ,  Haifeng Tang ,  Hao Wang ,  Christine Yang ,  Shu-Wei Yang

IPC分类号： A61K31/4439 ,  A61P31/04 ,  A61K31/407 ,  A61K31/421 ,  A61K31/422 ,  A61K31/427 ,  A61K31/431 ,  A61K31/4375 ,  A61K31/438 ,  A61K31/4709 ,  A61K31/5377 ,  A61K31/5383 ,  C07D263/26 ,  C07D413/04 ,  C07D413/06 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D471/04 ,  C07D491/048 ,  C07D495/04 ,  C07D498/04

CPC分类号： A61K31/4439 ,  A61K31/407 ,  A61K31/421 ,  A61K31/422 ,  A61K31/427 ,  A61K31/431 ,  A61K31/438 ,  A61K31/4375 ,  A61K31/4709 ,  A61K31/5377 ,  A61K31/5383 ,  A61P31/04 ,  C07D263/26 ,  C07D413/04 ,  C07D413/06 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D471/04 ,  C07D491/048 ,  C07D495/04 ,  C07D498/04

摘要： Novel compounds of the structural formula I, and the pharmaceutically acceptable salts thereof, are inhibitors of TarO and may be useful in the prevention, treatment and suppression of diseases mediated by TarO, such as bacterial infections, including gram negative bacterial infections and gram positive bacterial infections such as MRSA and MRSE, alone or in combination with a β-lactam antibiotic.

公开(公告)号：US20230266320A1

公开(公告)日：2023-08-24

申请号：US17779011

申请日：2020-11-20

申请人： MERCK SHARP & DOHME CORP.

发明人： Cindy J. Pauley ,  Lawrence William Dick, Jr. ,  Mary Lillian Shank Retzlaff ,  Matthew C. Troutman ,  Lynne Ireland Denny ,  Qiana M. Wilson ,  Kuo-Chang Yin

IPC分类号： G01N33/569

CPC分类号： G01N33/56994 ,  G01N2333/045 ,  G01N2470/04

摘要： The present invention relates to a method of detecting the presence of Cytomegalovirus and measuring antigenicity through detection and quantification of a pentameric complex by an indirect sandwich ELISA assay which ensures an appropriate concentration of this critical glycoprotein complex is present in the vaccine.

公开(公告)号：US20230192876A1

公开(公告)日：2023-06-22

申请号：US17772229

申请日：2020-10-29

申请人： Merck Sharp & Dohme Corp.

发明人： Elliot K. Chartash ,  Amy M. Beebe ,  Jason K. Cheung ,  Konstantin Dobrenkov ,  Claire H. Li ,  Richard Wnek

IPC分类号： C07K16/28 ,  A61P35/00 ,  A61K39/395 ,  A61K31/282 ,  A61K31/519

CPC分类号： C07K16/2878 ,  A61P35/00 ,  C07K16/2818 ,  C07K16/2827 ,  A61K39/3955 ,  A61K31/282 ,  A61K31/519 ,  A61K2039/505

摘要： The present invention relates to methods of treating cancer by administering an anti-CD27 antibody as a monotherapy or as a part of a combination thereof.